- Home
- SRV vs GALT Comparison
SRV vs GALT Comparison
Compare SRV & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRV | GALT |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.0M | 176.7M |
| IPO Year | 2007 | 2008 |
Fundamental Metrics
Financial Performance| Metric | SRV | GALT |
|---|---|---|
| Price | $43.12 | $3.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 59.6K | ★ 253.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.24 | $1.15 |
| 52 Week High | $46.40 | $7.13 |
Technical Indicators
Market Signals| Indicator | SRV | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 57.45 | 50.50 |
| Support Level | $42.15 | $2.90 |
| Resistance Level | $44.23 | $3.27 |
| Average True Range (ATR) | 0.76 | 0.20 |
| MACD | -0.07 | 0.05 |
| Stochastic Oscillator | 33.33 | 66.49 |
Price Performance
Historical ComparisonAbout SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.